Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study

Daniel A. Lim; Phiroz Tarapore; Edward Chang; Marlene Burt; Lenna Chakalian; Nicholas Barbaro; Susan Chang; Kathleen R. Lamborn; Michael W. McDermott

doi:10.1007/S11060-008-9781-4

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study

Daniel A. Lim, Phiroz Tarapore, Edward Chang, Marlene Burt, Lenna Chakalian, Nicholas Barbaro, Susan Chang, Kathleen R. Lamborn, Michael W. McDermott

Miami Neuroscience Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of neuro-oncology
Volume	93
DOIs	https://doi.org/10.1007/S11060-008-9781-4
State	Published - Jan 24 2009

Disciplines

Anesthesiology
Medicine and Health Sciences

Access to Document

10.1007/S11060-008-9781-4License: Unspecified

Cite this

Lim, D. A., Tarapore, P., Chang, E., Burt, M., Chakalian, L., Barbaro, N., Chang, S., Lamborn, K. R., & McDermott, M. W. (2009). Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. Journal of neuro-oncology, 93. https://doi.org/10.1007/S11060-008-9781-4

@article{8057d98088cd4a0ea39b6b9722d8e299,

title = "Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study",

author = "Lim, {Daniel A.} and Phiroz Tarapore and Edward Chang and Marlene Burt and Lenna Chakalian and Nicholas Barbaro and Susan Chang and Lamborn, {Kathleen R.} and McDermott, {Michael W.}",

note = "Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy. Levetiracetam (LEV) is a newer antiepileptic drug (AED) with fewer SEs and essentially no drug interactions.",

year = "2009",

month = jan,

day = "24",

doi = "10.1007/S11060-008-9781-4",

language = "American English",

volume = "93",

journal = "Journal of neuro-oncology",

}

TY - JOUR

T1 - Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study

AU - Lim, Daniel A.

AU - Tarapore, Phiroz

AU - Chang, Edward

AU - Burt, Marlene

AU - Chakalian, Lenna

AU - Barbaro, Nicholas

AU - Chang, Susan

AU - Lamborn, Kathleen R.

AU - McDermott, Michael W.

N1 - Seizures are common in patients with gliomas, and phenytoin (PHT) is frequently used to control tumor-related seizures. PHT, however, has many undesirable side effects (SEs) and drug interactions with glioma chemotherapy. Levetiracetam (LEV) is a newer antiepileptic drug (AED) with fewer SEs and essentially no drug interactions.

PY - 2009/1/24

Y1 - 2009/1/24

UR - http://europepmc.org/articles/PMC2687520

U2 - 10.1007/S11060-008-9781-4

DO - 10.1007/S11060-008-9781-4

M3 - Article

VL - 93

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -

Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study

Disciplines

Access to Document

Other files and links

Cite this